KINNATE BIOPHARMA INC's ticker is KNTE and the CUSIP is 49705R105. A total of 74 filers reported holding KINNATE BIOPHARMA INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 1.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,261,272 | -53.8% | 2,329,480 | 0.0% | 0.99% | -58.8% |
| Q2 2023 | $7,058,324 | -51.5% | 2,329,480 | 0.0% | 2.40% | -60.5% |
| Q1 2023 | $14,559,250 | +2.5% | 2,329,480 | 0.0% | 6.08% | +7.5% |
| Q4 2022 | $14,209,828 | -55.3% | 2,329,480 | -12.5% | 5.65% | -45.0% |
| Q3 2022 | $31,810,000 | -16.1% | 2,661,888 | -11.5% | 10.27% | -19.7% |
| Q2 2022 | $37,934,000 | +12.0% | 3,008,243 | 0.0% | 12.80% | +32.3% |
| Q1 2022 | $33,873,000 | -36.5% | 3,008,243 | 0.0% | 9.67% | -31.1% |
| Q4 2021 | $53,306,000 | – | 3,008,243 | – | 14.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 9,671,643 | $384,738,000 | 41.79% |
| Foresite Capital Management V, LLC | 875,001 | $34,808,000 | 25.78% |
| Vida Ventures Advisors, LLC | 2,747,074 | $109,279,000 | 22.43% |
| VR Adviser, LLC | 1,473,014 | $58,596,000 | 8.62% |
| RA Capital Management | 3,593,052 | $142,932,000 | 2.00% |
| Logos Global Management LP | 569,602 | $22,659,000 | 1.94% |
| Boxer Capital, LLC | 1,064,665 | $42,352,000 | 1.36% |
| Orbimed Advisors | 3,847,929 | $153,071,000 | 1.34% |
| HARVARD MANAGEMENT CO INC | 498,001 | $19,810,000 | 1.07% |
| DAFNA Capital Management LLC | 68,121 | $2,710,000 | 0.81% |